Abstract:The intracellular retention of nanotherapeutics is essential for their therapeutic activity. The immobilization of nanotherapeutics inside target cell types can regulate various cell behaviors. However, strategies for the intracellular immobilization of nanoparticles are limited. Herein, a cisplatin prodrug was synthesized and utilized as a glutathione (GSH)-activated linker to induce aggregation of the cisplatin prodrug/IR820/docetaxel nanoassembly. The nanoassembly has been reprogrammed with peptide-containing moieties for tumor-targeting and PD-1/PD-L1 blockade. The aggregation of the nanoassemblies is dependent on GSH concentration. Evaluations in vitro and in vivo revealed that GSH-induced intracellular aggregation of the nanoassemblies enhances therapeutic activity in primary tumors by enhancing the accumulation and prolonging the retention of the chemotherapeutics in the tumor site and inducing reactive oxygen species (ROS) generation and immunogenic cell death. Moreover, the nanoassemblies reinvigorate the immunocytes, especially the systemic immunocytes, and thereby alleviate pulmonary metastasis, even though the population of immunocytes in the primary tumor site is suppressed due to the enhanced accumulation of chemotherapeutics. This strategy provides a promising option for the intracellular immobilization of nanoparticles in vitro and in vivo.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is: how to enhance the effects of cancer chemotherapy and combined immunotherapy through the intracellular aggregation of nanomedicines. Specifically, the authors developed a new strategy, that is, by synthesizing cisplatin prodrug and using it as a glutathione (GSH) - responsive linker to induce the flocculation of small - molecule nano - assemblies intracellularly. This strategy aims to achieve the following goals: 1. **Increase the intracellular retention time of anticancer drugs**: By immobilizing nanomedicines inside target cells, the accumulation time and retention time of drugs at the tumor site can be prolonged, thereby improving the treatment effect. 2. **Regulate cell behavior**: The aggregation of intracellular nanomedicines can change cell behavior, for example, overcome drug resistance. 3. **Enhance chemotherapy and combined immunotherapy**: Intracellular aggregation not only enhances the chemotherapeutic effect, but also further promotes immunotherapy by inducing reactive oxygen species (ROS) generation and immunogenic cell death. ### Main research contents: - **Synthesize cisplatin prodrug**: By modifying cisplatin, it can react with GSH to generate hydroxylated cisplatin and further trigger intracellular aggregation. - **Construct peptide - reprogrammed small - molecule nano - assemblies**: Co - assemble cisplatin prodrug, polypeptide and other small - molecule drugs (such as paclitaxel, IR820, etc.) into nanoparticles. - **Evaluate GSH - induced intracellular aggregation**: Through in vitro and in vivo experiments, verify the influence of GSH concentration on the aggregation of nano - assemblies and its effect on cancer cells. - **Evaluate the treatment effect**: Through a variety of experimental means, including fluorescence imaging, cytotoxicity testing, immunohistochemical staining, etc., evaluate the potential of nano - assemblies in enhancing chemotherapy and combined immunotherapy. ### Key findings: - **GSH concentration - dependent intracellular aggregation**: When the GSH concentration exceeds a certain threshold, the nano - assemblies will rapidly aggregate, especially more obvious in the nano - assemblies containing FCDDP. - **Enhanced treatment effect**: Intracellular aggregation not only increases the accumulation of drugs at the tumor site, but also reduces the occurrence of lung metastasis by activating immune cells. - **Role of multifunctional peptide**: After introducing the multifunctional peptide CF27, the nano - assemblies show better tumor - targeting and immunomodulatory abilities. In conclusion, this study proposes an innovative method, which significantly improves the effects of cancer chemotherapy and combined immunotherapy through the controllable aggregation of intracellular nanomedicines.

Intracellular aggregation of peptide-reprogrammed small molecule nanoassemblies enhances cancer chemotherapy and combinatorial immunotherapy